The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007

European Journal of Health Economics

Volumn 14, Issue 1, 2013, Pages 41-56

  Lichtenberg, Frank R ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Innovation; Mortality; Orphan diseases; Orphan drugs; Rare diseases

Indexed keywords

ORPHAN DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BILE DUCT CANCER; BRAIN CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER INCIDENCE; CANCER MORTALITY; COLON CANCER; DRUG APPROVAL; DRUG MARKETING; DRUG USE; ESOPHAGUS CANCER; FAMILIAL CANCER; FRANCE; FRONTOTEMPORAL DEMENTIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; KIDNEY CARCINOMA; KIDNEY PELVIS CANCER; LEUKEMIA; LUNG CANCER; LUNG SMALL CELL CANCER; MORTALITY; MOUTH CANCER; MULTIPLE MYELOMA; MYELOMA; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PARKINSON DISEASE; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RARE DISEASE; RECTUM CANCER; STOMACH CANCER; SURVIVAL; TERATOMA; TESTIS CANCER; THYROID CANCER; UNITED STATES; UTERINE CERVIX CANCER; UTERUS CANCER;

ADOLESCENT; ADULT; AGED; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG APPROVAL; FRANCE; HUMANS; INFANT; LIFE TABLES; MIDDLE AGED; MODELS, STATISTICAL; MORTALITY, PREMATURE; NEOPLASMS; ORPHAN DRUG PRODUCTION; PHARMACEUTICAL PREPARATIONS; RARE DISEASES; UNITED STATES; YOUNG ADULT;

EID: 84872358725     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-011-0349-4     Document Type: Article

References (16)

1. Centre d'épidémiologie sur les causes médicales de décès, http://www.cepidc.vesinet.inserm.fr/
2. Centers for Disease Control: Compressed Mortality Database (http://wonder.cdc.gov/controller/datarequest/D43)
3. Centers for Disease Control: Multiple Cause-Of-Death Public-Use Data Files, http://www.cdc.gov/nchs/products/elec-prods/subject/mortmcd.htm
4. Cranston, J.W.; Williams, M.A.; Nielsen, N.H.; Bezman, R.J.; For the American Medical Association Council on Scientific Affairs: Unlabeled indications of food and drug administration: approved drugs. Drug Inf. J. 32, 1049-1061 (1998)
5. Food and Drug Administration: Drugs@FDA Database, http://www.fda.gov/ cder/drugsatfda/datafiles/default.htm
6. Food and Drug Administration: List of Orphan Designations and Approvals, http://www.fda.gov/orphan/designat/list.htm
7. Groupement pour l 'Elaboration et la Réalisation de Statistiques, http://www.gie-gers.fr/index.php3
8. Lichtenberg, F.R.: Pharmaceutical knowledge-capital accumulation and longevity. In: Carol, C.; John, H.; Dan, S. (eds.) Measuring Capital in the New Economy, pp. 237-269. University of Chicago Press, Chicago (2005)
9. Lichtenberg, F.R.: The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004. Econ. Innov. New Technol. 18(5), 407-428 (2009)
10. Lichtenberg, F.R.: Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. Health Econ. 18, 519-534 (2009)
11. Lichtenberg, F.R.; Waldfogel, J.: Does misery love company? Evidence from pharmaceutical markets before and after the orphan drug act. Mich. Telecomm. Tech. L. Rev. 335 (2009), http://www.mttlr.org/volfifteen/ lichtenberg&waldfogel.pdf
12. Liu, M.; Davis, K.: A Clinical Trials Manual from the Duke Clinical Research Institute: Lessons from a Horse Named Jim. Wiley, USA (2010)
13. National Cancer Institute: Cancer Prevalence Database, http://srab.cancer.gov/prevalence/canques.html
14. Orphanet: Prevalence of Rare Diseases: Bibliographic Data. Orphanet Report Series. Rare Diseases Collection, May 2010, Number 1: Listed in Alphabetical Order of Diseases, http://www.orpha.net/orphacom/cahiers/docs/GB/ Prevalence-of-rare-diseases-by-alphabetical-list.pdf
15. Répertoire des Spécialités Pharmaceutiques of the Agence Francaise de Securite Sanitaire des Produits de Sante, http://www.afssaps.sante.fr/htm/1/amm/amm0.htm
16. Romer, P.: Endogenous technical change. J. Polit. Econ. 98, S71-S102 (1990)